CL2016001429A1 - Formas polimórficas de un compuesto similar a un esteroide y metodos para la preparación y su uso - Google Patents

Formas polimórficas de un compuesto similar a un esteroide y metodos para la preparación y su uso

Info

Publication number
CL2016001429A1
CL2016001429A1 CL2016001429A CL2016001429A CL2016001429A1 CL 2016001429 A1 CL2016001429 A1 CL 2016001429A1 CL 2016001429 A CL2016001429 A CL 2016001429A CL 2016001429 A CL2016001429 A CL 2016001429A CL 2016001429 A1 CL2016001429 A1 CL 2016001429A1
Authority
CL
Chile
Prior art keywords
preparation
polymorphic forms
steroid
compound
methods
Prior art date
Application number
CL2016001429A
Other languages
English (en)
Inventor
Shaoxin Feng
Scott W Smith
Olivier M G Lambert
Suzanne Buttar
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52293229&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016001429(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CL2016001429A1 publication Critical patent/CL2016001429A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

FORMAS POLIMÓRFICAS Y AMORFAS DE BENZOATO 17-ALFA CORTISOL; MÉTODO DE PREPARACIÓN; COMPOSICIÓN FARMACÉUTICA QUE LAS COMPRENDE Y USO EN EL TRATAMIENTO DEL OJO SECO Y GLAUCOMA.
CL2016001429A 2013-12-13 2016-06-10 Formas polimórficas de un compuesto similar a un esteroide y metodos para la preparación y su uso CL2016001429A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361915589P 2013-12-13 2013-12-13

Publications (1)

Publication Number Publication Date
CL2016001429A1 true CL2016001429A1 (es) 2016-12-23

Family

ID=52293229

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016001429A CL2016001429A1 (es) 2013-12-13 2016-06-10 Formas polimórficas de un compuesto similar a un esteroide y metodos para la preparación y su uso

Country Status (17)

Country Link
US (1) US10065984B2 (es)
EP (1) EP3080140A2 (es)
JP (1) JP2016540001A (es)
KR (1) KR20160098338A (es)
CN (1) CN105814071A (es)
AR (1) AR098747A1 (es)
AU (1) AU2014361790B2 (es)
CA (1) CA2933371A1 (es)
CL (1) CL2016001429A1 (es)
IL (1) IL246059A0 (es)
MX (1) MX371012B (es)
PH (1) PH12016501098A1 (es)
SA (1) SA516371308B1 (es)
SG (2) SG11201604786QA (es)
TW (1) TWI659041B (es)
UA (1) UA121203C2 (es)
WO (1) WO2015089471A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019055028A1 (en) * 2017-09-15 2019-03-21 Kala Pharmaceuticals, Inc. PARTICLES, COMPOSITIONS AND METHODS FOR OPHTHALMIC APPLICATIONS AND / OR OTHER APPLICATIONS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6605514A (es) * 1966-04-25 1967-10-26
IT1056711B (it) * 1967-04-01 1982-02-20 Vismara F Spa Derivati dell idrocortisone
JPS52136157A (en) 1976-04-14 1977-11-14 Taisho Pharmaceut Co Ltd Preparation of steroid 17-esters
JPS54151958A (en) * 1978-05-19 1979-11-29 Taisho Pharmaceut Co Ltd Preparation of pregnane steroid 17alpha-ester
US8501800B2 (en) * 2009-03-05 2013-08-06 Insite Vision Incorporated Controlled-release ophthalmic vehicles
EP2619205B1 (en) * 2010-09-23 2017-05-17 AbbVie Bahamas Ltd. Monohydrate of an azaadamantane derivative
UA111867C2 (uk) * 2011-11-11 2016-06-24 Аллерган, Інк. ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ І СПОСІБ ЗАСТОСУВАННЯ ПОХІДНИХ 4-ПРЕГНЕН-11β-17-21-ТРІОЛ-3,20-ДІОНУ
CA2873214C (en) * 2012-05-11 2021-02-16 Reset Therapeutics, Inc. Carbazole-containing sulfonamides as cryptochrome modulators

Also Published As

Publication number Publication date
SA516371308B1 (ar) 2019-07-08
MX2016007718A (es) 2016-09-09
WO2015089471A3 (en) 2015-11-19
SG11201604786QA (en) 2016-07-28
KR20160098338A (ko) 2016-08-18
CA2933371A1 (en) 2015-06-18
TWI659041B (zh) 2019-05-11
MX371012B (es) 2020-01-10
EP3080140A2 (en) 2016-10-19
CN105814071A (zh) 2016-07-27
AU2014361790A1 (en) 2016-07-07
AU2014361790B2 (en) 2019-05-23
AR098747A1 (es) 2016-06-08
US10065984B2 (en) 2018-09-04
SG10201709987QA (en) 2018-01-30
TW201609788A (zh) 2016-03-16
UA121203C2 (uk) 2020-04-27
JP2016540001A (ja) 2016-12-22
IL246059A0 (en) 2016-07-31
PH12016501098A1 (en) 2016-08-15
WO2015089471A2 (en) 2015-06-18
US20150166597A1 (en) 2015-06-18

Similar Documents

Publication Publication Date Title
CL2015002855A1 (es) Derivados de oxopiridina sustituida.
CL2017003404A1 (es) Compuestos antibacterianos
BR112017001789A2 (pt) composições e métodos de uso para tratamento de distúrbios metabólicos
CL2018000542A1 (es) Nuevos derivados de fenoximetilo.
CL2016002877A1 (es) Compuestos de 2-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y métodos de uso de los mismos.
UY36311A (es) Indazoles sustituidos con bencilo
CL2014003444A1 (es) Compuestos derivados tienopirimidina; proceso de preparacion; composicion farmaceutica que los comprende; combinacion farmaceutica; uso en el tratamiento de canceres y enfermedades autoinmunes.
CL2013003019A1 (es) Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih.
CL2015001246A1 (es) Derivados de bendamustina y los metodos de su uso
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
ES2897914T8 (es) Compuestos que contienen nitrógeno, adecuados para el uso en la producción de poliuretanos
SMT201600069B (it) Composizioni comprendenti 15-hepe e metodi d’uso delle stesse
CL2015000976A1 (es) Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados.
AR106688A1 (es) PROCESO PARA PREPARAR UNA FORMULACIÓN EN POLVO SECO QUE COMPRENDE UN ANTICOLINÉRGICO, UN CORTICOSTEROIDE Y UN b-ADRENÉRGICO
CL2016001937A1 (es) Compuestos de benzopirano funcionalizados y uso de los mismos
ES2727103T8 (es) Conjugado anticuerpo-fármaco para IGF-1R y su utilización para el tratamiento del cáncer
GT201500143A (es) Composiciones que comprenden vortioxetina y donepezilo campo tecnico
SV2015005126A (es) Nuevos compuestos para el tratamiento del cáncer
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
CL2015000537A1 (es) Siarn y su uso en los métodos y composiciones para el tratamiento y/o prevención de enfermedades de los ojos.
BR112017001384A2 (pt) composto para uso em tratamento anti-helmíntico
BR112015021722A2 (pt) composição para uso no tratamento de síndrome do ovário policístico
BR112017011685A2 (pt) composições compreendendo 15-hepe e métodos de tratamento ou prevenção da fibrose usando as mesmas
CL2015003433A1 (es) Derivados de tilosina y método para su preparación
CR20160369A (es) Composiciones para uso en el tratamiento de afecciones alérgicas